This Biotech Stock Soared: Why One Fund Sold $3 Million
A biotech rally can be thrilling, but a large fund selling into the run-up often signals caution. This article unpack...
The debate between points and cash back is ongoing. Understand the benefits of each to determine which suits you best.
28,062 articlesA biotech rally can be thrilling, but a large fund selling into the run-up often signals caution. This article unpack...
Greg Abel’s early moves at Berkshire Hathaway signal a new investment ethos. This analysis breaks down the rationale,...
When wealth and fame meet legal drama, discovery battles can reshape costs and outcomes. This article breaks down the...
A seasoned pharma investor places a sizable bet on Nuvation Bio as a promising drug moves forward. Learn how insider ...
Oil climbs and stock futures rise as renewed U.S.-Iran clashes raise supply disruption fears in the Persian Gulf.
Jim Cramer argues that South Korea mispricing SK Hynix reflects trader psychology rather than weak fundamentals. He r...
As Warren Buffett steps back, Greg Abel’s potential move to buy a stock Buffett loves has investors buzzing. This art...
A Florida fraud case reveals how a Medicare supplier study spiraled into a $3.76 billion misbilling crisis. This arti...
A biotech stock sprinted 400% in a year, and an insider sale worth about $882k followed. The question for investors: ...
Active ETFs are reshaping how people think about investing. This article explains what they are, when they can beat p...
Patience and a long time horizon are the most powerful tools in any investor’s kit. This guide explains why waiting f...
RLJ Lodging Trust has fallen about 8% over the last 12 months. Yet a sizeable stake by a key investor suggests there ...